U.S. markets open in 4 hours 34 minutes
  • S&P Futures

    3,971.50
    -5.25 (-0.13%)
     
  • Dow Futures

    32,065.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    11,888.25
    -54.00 (-0.45%)
     
  • Russell 2000 Futures

    1,797.70
    +0.90 (+0.05%)
     
  • Crude Oil

    111.01
    +0.68 (+0.62%)
     
  • Gold

    1,846.00
    -0.30 (-0.02%)
     
  • Silver

    21.80
    -0.07 (-0.32%)
     
  • EUR/USD

    1.0687
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.7490
    0.0000 (0.00%)
     
  • Vix

    28.41
    -1.04 (-3.53%)
     
  • GBP/USD

    1.2567
    -0.0011 (-0.09%)
     
  • USD/JPY

    126.6670
    -0.5740 (-0.45%)
     
  • BTC-USD

    29,033.36
    -814.41 (-2.73%)
     
  • CMC Crypto 200

    636.34
    -34.67 (-5.17%)
     
  • FTSE 100

    7,519.07
    -3.68 (-0.05%)
     
  • Nikkei 225

    26,604.84
    -72.96 (-0.27%)
     

POSEIDA THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Poseida Therapeutics, Inc. on Behalf of Poseida Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Poseida Therapeutics, Inc. (NASDAQ: PSTX) on behalf of Poseida stockholders. Our investigation concerns whether Poseida has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On or around July 10, 2020, Poseida completed its initial public offering (“IPO”), issuing 14 million shares of common stock priced at $16.00 per share.

Then, on August 18, 2020, Poseida disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on Poseida’s Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer. The FDA placed the hold in order to investigate a patient’s death that occurred in late July.

On this news, Poseida’s stock price fell $3.94 per share, or 30.31%, to close at $9.06 per share on August 18, 2020.

If you purchased or otherwise acquired Poseida Therapeutics shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com